This article is more than 5 years old. Information may no longer be current.
Spot stenting lowers patency, TLR vs. full stenting in femoropopliteal lesions
Click Here to Manage Email Alerts
SAN DIEGO — Patients with peripheral artery disease who were treated with spot stenting for femoropopliteal lesions had lower rates of primary patency and clinically driven target lesion revascularization compared with those treated with full coverage stenting, according to data presented at TCT 2018.
Yusuke Tomoi, MD, of the department of cardiology at Kokura Memorial Hospital in Kitakyushu, Japan, and colleagues analyzed data from 1,151 patients with symptomatic PAD who underwent femoropopliteal endovascular therapy with stenting between 2010 and 2016.
The primary endpoint was primary patency at 3 years, and the secondary endpoint was propensity-matched clinically driven TLR at 3 years.
Spot stenting resulted in lower primary patency compared with full coverage stenting (P = .011).
However, clinically driven TLR at 3 years occurred less often in patients treated with spot stenting vs. full coverage stenting (P = .014).
Lesion location A, chronic total occlusion lesions and lesion length of at least 138 mm were linked to the noninferiority of spot stenting vs. full coverage stenting regarding primary patency.
“Interaction analysis suggested that spot stenting might be suited to more complex [femoropopliteal] lesions,” Tomoi said during the presentation. – by Darlene Dobkowski
References:
Tomoi Y, et al. Abstract 116. Presented at: TCT Scientific Symposium; Sept. 21-25, 2018; San Diego.
Tomoi Y, et al. J Am Coll Cardiol. 2018;doi:10.1016/j.jacc.2018.08.1218.
Disclosure: Tomoi reports no relevant financial disclosures.